Status:
TERMINATED
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis
Lead Sponsor:
Centocor, Inc.
Collaborating Sponsors:
The Cleveland Clinic
Conditions:
Giant Cell Arteritis
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and efficacy (effectiveness) of Infliximab (Remicade) in patients with Giant Cell Arteritis. Infliximab (Remicade) targets specific proteins in the ...
Detailed Description
The purpose of this study is to see if infliximab is safe and effective in treating GCA. Currently, the only treatment for GCA is prednisone. GCA is a long lasting inflammatory disease. The cause is u...
Eligibility Criteria
Inclusion
- Patients who have a diagnosis of Giant Cell Arteritis (GCA)
- Patients who have a diagnosis of GCA of = 4 weeks' duration
- Patients who are receiving = 40 mg/day of prednisone/prednisolone
Exclusion
- Patients must not have a prior diagnosis of GCA \> 4 weeks
- Patients must not have failed to respond to glucocorticosteroid therapy within 5 days of initiation of therapy.
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2005
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT00076726
Start Date
November 1 2003
End Date
July 1 2005
Last Update
May 17 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.